Incretin Mimetics and Amylin Analogues

FDA

• Incretin mimetics also knownn as GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, semaglutide and dulaglutide): type 2 diabetes (T2DM), although insufficient data to support use in conjunction with prandial insulin.
  • High-dose liraglutide (Saxenda™) and semaglutide (Wegovy™): chronic weight management, adjunct to a reduced-calorie diet and increased physical activity in adult patients with an initial body mass index of 30 kg/m² or greater (obese) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. T2DM, hypertension, dyslipidemia)
• Amylin analogues (pramlintide): type 1 diabetes (T1DM) or T2DM on insulin therapy.